Rev Actualizado.

1. Lo más Significativo de ASCO
2013 en Cáncer de Mama
Dr. C. Med. Jorge L. Soriano García
Servicio Oncología Clínica
Hospital “Hermanos Ameijeiras”
Dra. Maurenis Hernández
División de Ensayos Clínicos
Centro de Inmunología Molecular

2. Basal like
HER2+
Luminal A
Luminal B
Resultados clínicos
Clasificación Molecular
Cáncer de Mama: Diagnóstico

3. Cáncer de Mama: Tratamiento Sistémico
Subtipo Tipo de Tratamiento Observaciones
Luminal A HT solamente
QT  >3 ganglios axilares
metastásicos.
Luminal B
(HER2 negativo)*
HT ± QT
Luminal B
(HER2 positivo)
QT + anti-HER2 + HT
HER2 positivo
(no luminal)
QT + anti-HER2
Pacientes con bajo riesgo (<0,5
cm)  observación.
Triple negativo
(ductal)
QT No Estándar

4. [TITLE]
Presented By Joseph A. Sparano, MD at 2013 ASCO Annual Meeting

5. [TITLE]
Presented By Joseph A. Sparano, MD at 2013 ASCO Annual Meeting

6. [TITLE]
Presented By Joseph A. Sparano, MD at 2013 ASCO Annual Meeting

7. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

8. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

9. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

10. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

11. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

12. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

13. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

14. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

15. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

16. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

17. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

18. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

19. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

20. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

21. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

22. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

23. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

24. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

25. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

26. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

27. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

28. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

29. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

30. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

31. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

32. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

33. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

34. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

35. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

36. [TITLE]
Presented By Deborah Toppmeyer, MD at 2013 ASCO Annual Meeting

37. [TITLE]
Presented By Ines Maria Vaz Duarte Luis, MD at 2013 ASCO Annual Meeting

38. [TITLE]
Presented By Ines Maria Vaz Duarte Luis, MD at 2013 ASCO Annual Meeting

39. [TITLE]
Presented By Ines Maria Vaz Duarte Luis, MD at 2013 ASCO Annual Meeting

40. Lo más Significativo de ASCO
2013 en Cáncer de Mama
HER-2 (+)

41. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

42. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

43. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

44. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

45. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

46. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

47. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

48. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

49. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

50. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

51. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

52. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

53. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

54. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

55. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

56. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

57. [TITLE]
Presented By Martine J. Piccart-Gebhart, MD, PhD at 2013 ASCO Annual Meeting

58. [TITLE]
Presented By David A. Cameron, MD, FRCP at 2013 ASCO Annual Meeting

59. [TITLE]
Presented By David A. Cameron, MD, FRCP at 2013 ASCO Annual Meeting

60. [TITLE]
Presented By David A. Cameron, MD, FRCP at 2013 ASCO Annual Meeting

61. Para Cuba: Qué Hacer?????
 Incrementar la disponibilidad y accesibilidad a las técnicas de
IHQ
 Aumentar la disponibilidad de tratamiento hormonal y de
terapia anti-Her2
 Introducción tecnológica de la técnica del ganglio centinela
 Aumentar la inclusión de pacientes en los
EC Nacionales y la participación en EC con
grupos cooperativos internacionales.
 CUMPLIMIENTO ESTRICTO DE LA GUÍA DE
PRÁCTICA CLÍNICA EN CÁNCER DE MAMA